Login
$KTTA
$0.50 -$0.02 (4.21%) Live

$KTTA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 8-K: Regulation FD Disclosure

(Former name or former address, if changed since last report.)

16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 QUARTERLY REPORT
06 Nov 2026 SCHEDULE 13G/A
16 Sep 2026 25-NSE
16 Sep 2026 8-K: Other Events

The warrants of Pasithea Therapeutics Corp. (the “Company”) to purchase shares of the Company's common stock, which trade on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KTTAW” (the “Warrants”), will expire on September 17, 202...

09 Sep 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 9, 2026, the Company held its Annual Meeting. The stockholders of the Company acted upon the following three proposals at the Annual Meeting: (1) the election of two Class III directors; (2) the ratification of the appointme...

21 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously reported, on February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon th...

14 Aug 2026 QUARTERLY REPORT
14 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 FORM ARS
07 Aug 2026 Proxy statement: annual meeting on September 9, 2026
31 Jul 2026 SCHEDULE 13G/A
29 Jul 2026 PRELIMINARY PROXY STATEMENT
01 Jul 2026 SCHEDULE 13G/A
23 Jun 2026 SCHEDULE 13G
22 Jun 2026 Form 4: Coastlands Capital Lp, 10% owner

Bought 100,000 shares ($53K)

15 May 2026 QUARTERLY REPORT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support